Full text is available at the source.
Abstract
NAD⁺ supplementation may influence cellular energy metabolism and signaling pathways linked to aging and metabolic health.
- Oral NAD⁺ precursors like nicotinamide riboside and nicotinamide mononucleotide can elevate circulating NAD⁺ levels.
- The clinical benefits of these precursors are variable and depend on context.
- Intravenous NAD⁺ administration lacks robust clinical validation and is not well characterized.
- NAD⁺ responses are nonlinear, affected by factors such as dose, age, metabolic state, and administration route.
- Supplementation does not follow a simple dose-response relationship but operates within a complex regulatory system.
Simplified